Abstract: Disclosed are a new AXL-targeting monoclonal antibody and antibody-drug conjugate. Also disclosed is a method for preparing said antibody and antibody-drug conjugate. The AXL antibody of the present invention can bind with purified human AXL protein and multiple AXL on tumor cell surface with high effectiveness and high specificity. Said humanized antibody also has high affinity and low immunogenicity. Said AXL antibody-drug conjugate has markable performance against tumors having high AXL expression.

Abstract: A wireless charging device includes a shell, a coil assembly, a main board assembly and a heat dissipation assembly. The shell is defined with first and second air ports, the coil assembly and the main board assembly are located in the shell, the heat dissipation assembly is used for dissipating heat of the coil assembly and the main board assembly. The heat dissipation assembly includes a heat sink and a fan, the heat sink includes a first side and a second side facing away from each other, the coil assembly is arranged on the first side, the fan is arranged on the second side, and the fan is defined with third and fourth air ports. The first air port, the second air port, the third air port and the fourth air port are in communication with one another to form a heat-dissipation air passage located on the second side.

Abstract: This application discloses a media file presentation method, a client application, and a plug-in. The method includes: sending a media information obtaining request to a plug-in installed in the client application, so that the plug-in obtains first brief information and second brief information of a media file from a server based on the media information obtaining request; and receiving a notification message for the media file from the plug-in; and presenting the first brief information at a first presentation position according to the notification message, and then presenting the second brief information at a second presentation position, the media file being obtained and presented when an operation performed by a user on the second brief information is received.

Abstract: The present disclosure discloses a media information processing method, a mobile terminal, and a storage medium. The method includes: determining that a condition for presenting media information in a graphical interface of an application is satisfied; requesting media information and a control policy of the media information from a server; loading the control policy in the application, and determining that a form needs to be used in the media information to obtain information from a user; requesting a WebView page adapted to the form from the server, the WebView page being obtained by initializing a WebView template based on a customized parameter of the form; and presenting the media information in the graphical interface of the application, and loading the WebView page in the graphical interface of the application.

Abstract: The present disclosure discloses a media information processing method, a mobile terminal, and a storage medium. The method includes: determining that a condition for presenting media information in a graphical interface of an application is satisfied; requesting media information and a control policy of the media information from a server; loading the control policy in the application, and determining that a form needs to be used in the media information to obtain information from a user; requesting a WebView page adapted to the form from the server, the WebView page being obtained by initializing a WebView template based on a customized parameter of the form; and presenting the media information in the graphical interface of the application, and loading the WebView page in the graphical interface of the application.

Abstract: The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal D1-D2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from D1-D2 coupling and/or activation. Agents of the present invention include fragments of D2 receptor or D1 receptor that can disrupt D1-D2 coupling.

Abstract: The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal D1-D2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from D1-D2 coupling and/or activation. Agents of the present invention include fragments of D2 receptor or D1 receptor that can disrupt D1-D2 coupling.

Abstract: The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal D1-D2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from D1-D2 coupling and/or activation. Agents of the present invention include fragments of D2 receptor or D1 receptor that can disrupt D1-D2 coupling.

Abstract: A mouse device used on a surface includes a main body, a circuit assembly and a back cover. The main body includes a bottom and at least one slot formed at the bottom. The circuit assembly is disposed within the main body and executing a default function of the mouse device. The back cover comprises a first side, a second side, at least one hook at the first side, and a plurality of pads at the second side. The back cover contacts with the surface via the plurality of the pads, is disposed detachably at the bottom of the main body and is buckled to the slot by the hook.

Abstract: The invention provides anti-Axl antibodies and methods of using the same.

Abstract: A mouse device used on a surface includes a main body, a circuit assembly and a back cover. The main body includes a bottom and at least one slot formed at the bottom. The circuit assembly is disposed within the main body and executing a default function of the mouse device. The back cover comprises a first side, a second side, at least one hook at the first side, and a plurality of pads at the second side. The back cover contacts with the surface via the plurality of the pads, is disposed detachably at the bottom of the main body and is buckled to the slot by the hook.

Abstract: The invention provides anti-Axl antibodies and methods of using the same.

Abstract: A handset device (10) includes a substrate (56) defining a first audio port portion (78) and having a contact pad (266). An adhesive (60) is operatively coupled to the substrate (56). The adhesive (60) defines a second audio port portion (276) stacked with the first audio port portion (278) and defines a first electrical port portion (262). A speaker (32) having an electrical connector (238) is operatively coupled to the contact pad (266) through the first electrical port portion (262). The adhesive (60) is operative to seal the first and second audio port portions (278 and 276) from the electrical port portion (262). In addition, in one example, the handset device (10) may include a substrate (56) defining a first audio port portion (278), a speaker (32) operatively coupled to the substrate (56), and a rear housing (20) operatively coupled to the substrate (56) and defining an audio cavity (1104).

Abstract: A display for a mobile communication device is disclosed. The display may include a first layer with refractive index n1, having at least a rough surface on one side, a second layer, having refractive index n2, applied contiguously on a side opposite from the rough side of the first layer, wherein n1>n2>nair and nair, is the refractive index in air media, a reflective display disposed on a side of the second layer opposite from the first layer, and at least one light source located adjacent to at least one edge or side of the first layer.

Abstract: A handset device (10) includes a substrate (56) defining a first audio port portion (78) and having a contact pad (266). An adhesive (60) is operatively coupled to the substrate (56). The adhesive (60) defines a second audio port portion (276) stacked with the first audio port portion (278) and defines a first electrical port portion (262). A speaker (32) having an electrical connector (238) is operatively coupled to the contact pad (266) through the first electrical port portion (262). The adhesive (60) is operative to seal the first and second audio port portions (278 and 276) from the electrical port portion (262). In addition, in one example, the handset device (10) may include a substrate (56) defining a first audio port portion (278), a speaker (32) operatively coupled to the substrate (56), and a rear housing (20) operatively coupled to the substrate (56) and defining an audio cavity (1104).

Abstract: Polypeptides are expressed by the pituitary-tumor-transforming-gene (PTTG), formerly known as pituitary-tumor-specific-gene (PTTG), and nucleic acids encode them. Examples are the human and rat PTTG proteins. The nucleic acids may be applied to the production of a recombinant protein, and to the detection of the presence of PTTG genes in different species. The nucleic acids may be operatively linked to a vector, optionally provided with control and expression sequences and/or being carried by a host cell. The nucleic acids may also be delivered to a mammal to compensate for the absence, or a defective expression, of endogenous protein. The nucleic acids, proteins, and antibodies are also employed in disgnostic assays, as well as, for example, in the production of anti-PTTG antibodies (protein), therapeutic compositions and other applications of the proteins and antibodies. Various kits utilize nucleic acids, polypeptides, and/or antibodies. A transgenic non-human mammal expresses PTTG.

Abstract: Polypeptides are expressed by the pituitary-tumor-transforming-gene (PTTG), formerly known as pituitary-tumor-specific-gene (PTSG), and nucleic acids encode them. Examples are the human and rat PTTG proteins. The nucleic acids may be applied to the production of a recombinant protein, and to the detection of the presence of PTTG genes in different species. The nucleic acids may be operatively linked to a vector, optionally provided with control and expression sequences and/or being carried by a host cell. The nucleic acids may also be delivered to a mammal to compensate for the absence, or a defective expression, of endogenous protein. The nucleic acids, proteins, and antibodies are also employed in disgnostic assays, as well as, for example, in the production of anti-PTTG antibodies (protein), therapeutic compositions and other applications of the proteins and antibodies. Various kits utilize nucleic acids, polypeptides, and/or antibodies. A transgenic non-human mammal expresses PTTG.

Abstract: Polypeptides are expressed by the pituitary-tumor-transforming-gene (PTTG), formerly known as pituitary-tumor-specific-gene (PTSG), and nucleic acids encode them. Examples are the human and rat PTTG proteins. The nucleic acids may be applied to the production of a recombinant protein, and to the detection of the presence of PTTG genes in different species. The nucleic acids may be operatively linked to a vector, optionally provided with control and expression sequences and/or being carried by a host cell. The nucleic acids may also be delivered to a mammal to compensate for the absence, or a defective expression, of endogenous protein. The nucleic acids, proteins, and antibodies are also employed in disgnostic assays, as well as, for example, in the production of anti-PTTG antibodies (protein), therapeutic compositions and other applications of the proteins and antibodies. Various kits utilize nucleic acids, polypeptides, and/or antibodies. A transgenic non-human mammal expresses PTTG.

Abstract: Polypeptides are expressed by the pituitary-tumor-transforming-gene (PTTG), formerly known as pituitary-tumor-specific-gene (PTSG), and nucleic acids encode them. Examples are the human and rat PTTG proteins. The nucleic acids may be applied to the production of a recombinant protein, and to the detection of the presence of PTTG genes in different species. The nucleic acids may be operatively linked to a vector, optionally provided with control and expression sequences and/or being carried by a host cell. The nucleic acids may also be delivered to a mammal to compensate for the absence, or a defective expression, of endogenous protein. The nucleic acids, proteins, and antibodies are also employed in diagnostic assays, as well as, for example, in the production of anti-PTTG antibodies (protein), therapeutic compositions and other applications of the proteins and antibodies. Various kits utilize nucleic acids, polypeptides, and/or antibodies. A transgenic non-human mammal expresses PTTG.

Abstract: The invention provides anti-Axl antibodies and methods of using the same.